MannKind Co. (NASDAQ:MNKD) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in shares of MannKind Co. (NASDAQ:MNKDFree Report) by 135.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 166,770 shares of the biopharmaceutical company’s stock after acquiring an additional 95,893 shares during the quarter. SG Americas Securities LLC owned about 0.06% of MannKind worth $607,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in MNKD. State Street Corp increased its stake in shares of MannKind by 66.6% during the third quarter. State Street Corp now owns 20,832,244 shares of the biopharmaceutical company’s stock valued at $64,372,000 after acquiring an additional 8,331,058 shares during the period. Millennium Management LLC increased its stake in shares of MannKind by 144.6% during the fourth quarter. Millennium Management LLC now owns 6,249,939 shares of the biopharmaceutical company’s stock valued at $32,937,000 after acquiring an additional 3,695,224 shares during the period. Two Sigma Advisers LP increased its stake in shares of MannKind by 786.7% during the first quarter. Two Sigma Advisers LP now owns 2,048,427 shares of the biopharmaceutical company’s stock valued at $8,399,000 after acquiring an additional 1,817,400 shares during the period. Two Sigma Investments LP increased its stake in shares of MannKind by 106.6% during the first quarter. Two Sigma Investments LP now owns 3,071,455 shares of the biopharmaceutical company’s stock valued at $12,593,000 after acquiring an additional 1,584,567 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of MannKind by 108.3% during the first quarter. Bank of America Corp DE now owns 2,838,103 shares of the biopharmaceutical company’s stock valued at $11,636,000 after acquiring an additional 1,475,480 shares during the period. Institutional investors and hedge funds own 49.55% of the company’s stock.

MannKind Stock Performance

NASDAQ MNKD opened at $4.43 on Thursday. MannKind Co. has a twelve month low of $3.17 and a twelve month high of $5.75. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -88.60 and a beta of 1.28. The firm’s 50 day moving average price is $4.09 and its two-hundred day moving average price is $3.90.

MannKind (NASDAQ:MNKDGet Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.02. The firm had revenue of $58.47 million for the quarter, compared to analysts’ expectations of $52.36 million. On average, research analysts forecast that MannKind Co. will post 0.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MNKD has been the topic of several recent research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $6.50 price target on shares of MannKind in a research report on Friday, March 15th. Wedbush restated an “outperform” rating and issued a $10.00 price target on shares of MannKind in a research report on Wednesday, February 28th. Finally, HC Wainwright restated a “buy” rating and issued a $7.50 price target on shares of MannKind in a research report on Thursday, January 4th.

Check Out Our Latest Report on MannKind

About MannKind

(Free Report)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.

Read More

Want to see what other hedge funds are holding MNKD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MannKind Co. (NASDAQ:MNKDFree Report).

Institutional Ownership by Quarter for MannKind (NASDAQ:MNKD)

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.